At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Pediatric Patients with Hemophilia A
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of once weekly injections of the study drug in children with hemophilia A and FVIII inhibitors who are currently receiving treatment with FEIBA or NovoSeven drugs. This study will also be evaluating the reduction in the number of bleeds over time while you are receiving the study drug.
In order to participate you must meet the following criteria:
- Are a male or female under the age of 18 years old.
- Have hemophilia A with an inhibitor.
- Weigh less than 40 kg.
- Require bypassing agents such as Feiba or NovoSeven.
This is a partial list of elgibility requirements.